Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV-X System for Corneal Collagen Cross-Linking in Progressive Keratoconus
NCT00647699Phase 3Completed
- Sponsor
- Glaukos Corporation
- Start
- Dec 2007
- Primary completion
- Apr 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of riboflavin in keratoconus (2 arms), sponsored by Glaukos Corporation. Primary endpoint: Mean Change From Baseline in Maximum Keratometry at 12 months. Started Dec 2007; status: completed.
02
Drugs
riboflavin
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT00647699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00647699.